We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

18 hedge funds and large institutions have $573K invested in Theriva Biologics in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

20% more funds holding

Funds holding: 15 → 18 (+3)

0.02% less ownership

Funds ownership: 0.27% → 0.25% (-0.02%)

43% less capital invested

Capital invested by funds: $1.01M → $573K (-$435K)

Holders
18
Holders Change
+3
Holders Change %
+20%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$15.1K
2
Jane Street
Jane Street
New York
+$10.5K
3
TSS
Two Sigma Securities
New York
+$9.72K
4
Renaissance Technologies
Renaissance Technologies
New York
+$9.43K
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$61

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$7.66K
2
UBS Group
UBS Group
Switzerland
-$5.93K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$277K -$7.66K -504 -2%
BlackRock
2
BlackRock
New York
$103K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$76.2K +$15.1K +995 +21%
Renaissance Technologies
4
Renaissance Technologies
New York
$29K +$9.43K +620 +40%
State Street
5
State Street
Massachusetts
$26.3K – – –
BCM
6
Bridgeway Capital Management
Texas
$15.4K – – –
Northern Trust
7
Northern Trust
Illinois
$14.3K – – –
Jane Street
8
Jane Street
New York
$9.35K +$10.5K +693 New
TSS
9
Two Sigma Securities
New York
$8.61K +$9.72K +639 New
Charles Schwab
10
Charles Schwab
California
$7.32K – – –
Fisher Asset Management
11
Fisher Asset Management
Washington
$6.78K – – –
IA
12
IFP Advisors
Florida
$206 – – –
TRCT
13
Tower Research Capital (TRC)
New York
$78 – – –
Wells Fargo
14
Wells Fargo
California
$67 +$15 +1 +25%
Fidelity Investments
15
Fidelity Investments
Massachusetts
$54 +$61 +4 New
Osaic Holdings
16
Osaic Holdings
Arizona
$47 +$30 +2 +100%
SPIA
17
Steward Partners Investment Advisory
New York
$8 – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$8 +$15 +1 New
Morgan Stanley
19
Morgan Stanley
New York
$5 – – –
Bank of America
20
Bank of America
North Carolina
$3 – – –
UBS Group
21
UBS Group
Switzerland
– -$5.93K -237 Closed

TOVX Hedge Fund Activity: Q3 2023 in Review

18 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2023, worth a combined $573K — down 43% from $1.01M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TOVX positions and 1 closed out — a net gain of 3 holders — while 4 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $15.1K. The largest seller was Vanguard Group, cutting an estimated $7.66K.

  • 18 institutional investors held Theriva Biologics (TOVX) as of Q3 2023, up from 15 in Q2 2023.
  • Funds reported $573K of Theriva Biologics stock for Q3 2023, down 43% quarter-over-quarter.
  • 4 funds opened new Theriva Biologics positions in Q3 2023 and 1 closed out, a net change of +3 holders.
  • The largest Theriva Biologics buyer in Q3 2023 was Geode Capital Management, an estimated $15.1K added.
  • The largest Theriva Biologics seller in Q3 2023 was Vanguard Group, an estimated $7.66K sold.

Based on aggregated 13F filings for Q3 2023.